1 September 2023 - On the basis of the available data, there is a hint of a non-quantifiable added benefit for patients under 65 years for whom high dose therapy is an option.

Among other things, lisocabtagene maraleucel is approved for the treatment of adults with different forms of B-cell lymphoma, namely diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and grade 3B follicular lymphoma that relapse within 12 months of completion of first-line chemoimmunotherapy or are refractory to that therapy.

Read IQWiG press release